These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 32427692)
1. The role of PPARα in autosomal dominant polycystic kidney disease. Lakhia R Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):432-438. PubMed ID: 32427692 [TBL] [Abstract][Full Text] [Related]
2. PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice. Lakhia R; Yheskel M; Flaten A; Quittner-Strom EB; Holland WL; Patel V Am J Physiol Renal Physiol; 2018 Jan; 314(1):F122-F131. PubMed ID: 28903946 [TBL] [Abstract][Full Text] [Related]
3. microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Hajarnis S; Lakhia R; Yheskel M; Williams D; Sorourian M; Liu X; Aboudehen K; Zhang S; Kersjes K; Galasso R; Li J; Kaimal V; Lockton S; Davis S; Flaten A; Johnson JA; Holland WL; Kusminski CM; Scherer PE; Harris PC; Trudel M; Wallace DP; Igarashi P; Lee EC; Androsavich JR; Patel V Nat Commun; 2017 Feb; 8():14395. PubMed ID: 28205547 [TBL] [Abstract][Full Text] [Related]
4. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302 [TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease. Ishimoto Y; Inagi R; Yoshihara D; Kugita M; Nagao S; Shimizu A; Takeda N; Wake M; Honda K; Zhou J; Nangaku M Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993480 [TBL] [Abstract][Full Text] [Related]
6. Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. He J; Zhou H; Meng J; Zhang S; Li X; Wang S; Shao G; Jin W; Geng X; Zhu S; Yang B Pharmacol Res; 2020 May; 155():104751. PubMed ID: 32151678 [TBL] [Abstract][Full Text] [Related]
7. Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). Nikonova AS; Deneka AY; Kiseleva AA; Korobeynikov V; Gaponova A; Serebriiskii IG; Kopp MC; Hensley HH; Seeger-Nukpezah TN; Somlo S; Proia DA; Golemis EA FASEB J; 2018 May; 32(5):2735-2746. PubMed ID: 29401581 [TBL] [Abstract][Full Text] [Related]
8. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817 [TBL] [Abstract][Full Text] [Related]
9. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. Chen L; Zhou X; Fan LX; Yao Y; Swenson-Fields KI; Gadjeva M; Wallace DP; Peters DJ; Yu A; Grantham JJ; Li X J Clin Invest; 2015 Jun; 125(6):2399-412. PubMed ID: 25961459 [TBL] [Abstract][Full Text] [Related]
10. Role of keratinocyte growth factor in the pathogenesis of autosomal dominant polycystic kidney disease. Mei C; Mao Z; Shen X; Wang W; Dai B; Tang B; Wu Y; Cao Y; Zhang S; Zhao H; Sun T Nephrol Dial Transplant; 2005 Nov; 20(11):2368-75. PubMed ID: 16141466 [TBL] [Abstract][Full Text] [Related]